maximus tribe glp 1 reviews Maximus Tribe Semaglutide: Program Details,

GLP-1 receptor agonists have well-characterized safety profiles based on extensive use in diabetes and obesity management, but specific considerations apply when considering their use in patients with substance use disorders

[3] Dicke WK

51 Gallbladder Disease Rapid weight loss can increase the risk of cholelithiasis and cholecystitis, and was observed in major GLP-1RA trials

will finally come of age with the biomarker in the TL1A studies Consider clinical clues cytokine-based strategies The presence of other IMIDS gives clues to dominant biological process and therefore clues to treatment target FUTURE CONSIDERATIONS Emerging endpoints of interest Transmural healing Disease clearance Collateral remission (rheumatology) or functional remission In progress STRIDE III (end 2025 / 26) New(er) and novel treatments Improving existing MoAs New MoAs novel small molecules, mucosal healing agents, cellular immunotherapy Pulse and de-escalation strategies Biome-based strategies Dietary strategies elimination